Deals & IPOs

L'Oreal Settles First Hair Relaxer Cancer Trial in Chicago

L'Oreal's US unit settled the first hair relaxer cancer trial in Chicago on Nov. 16 for a confidential sum, with more than 12,700 federal cases still pending.

By Daniel Okafor

3 min read

L’Oreal US Settles Hair Relaxer Cancer Cases During First Trial
L’Oreal US Settles Hair Relaxer Cancer Cases During First TrialAmari Shutters / unsplash

What's News

  • L'Oreal's US subsidiary settled the first hair relaxer cancer trial on Nov. 16 for a confidential sum.
  • More than 12,700 federal cases over the claims are centralized before a judge in Chicago.
  • A 2022 NIH study found frequent users of chemical straighteners were more than twice as likely to develop uterine cancer.
  • Arizona and Minnesota sued L'Oreal this year, alleging the company misled women about product safety.

L'Oreal's US subsidiary settled the first hair relaxer cancer case to reach trial, cutting short a Chicago jury proceeding on Nov. 16 on confidential terms. Four women who blamed chemical hair straighteners for their gynecologic cancers accepted the deal midway through a trial that had begun with jury selection on Nov. 9, according to their attorneys.

The settlement closes the opening test of a litigation wave that now counts more than 12,700 federal cases, centralized before a judge in Chicago, according to court records. Additional suits sit in state courts.

Who sued, and over what?

The four plaintiffs are MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson. They filed suit against L'Oreal's US subsidiary and several other makers of the products in Cook County, Illinois, in 2023 and 2024. They alleged that years of using chemical hair straighteners caused them to develop gynecologic cancers.

Their attorney, Danielle Ward Mason, said in a statement that she hoped the settlement would give the women a sense of justice. The lawyers said the sum stays confidential.

The products at issue were marketed under the names Dark and Lovely, Optimum and other brands. They promise to permanently straighten textured hair and have been widely marketed to Black women.

What started the litigation?

The first lawsuits hit the docket after 2022. That year, the National Institutes of Health released a study finding that women who used chemical hair straighteners several times a year were more than twice as likely to develop uterine cancer.

L'Oreal has pushed back on the science. The company said the NIH study did not establish a causal link between the use of the products and any conditions alleged by the plaintiffs.

A spokesperson for L'Oreal said the company's highest priority is the health and wellbeing of its consumers. The company remains confident in the safety of its SoftSheen-Carson brand hair products, which include hair relaxers.

"L'Oréal USA strictly follows all regulations in every market in which it operates, and its products are always subject to a rigorous scientific evaluation of their safety," the spokesperson said.

What does the settlement change?

The deal ends the first trial but resolves only four claims out of thousands. More than 12,700 cases remain centralized before a federal judge in Chicago, and those plaintiffs now know L'Oreal will pay rather than face a jury verdict on the NIH findings. A confidential sum buys silence on the price of that risk.

State attorneys general have joined the fight. At least two states, Arizona and Minnesota, sued L'Oreal over the products this year. Both states allege the company misled women about the products' safety.

The stakes cut both ways for the company. Settling the first trial avoids a public airing of internal documents and a possible punitive damages award, but it also signals to the remaining plaintiffs that settlement offers are on the table. The size of the wave — four cases settled, more than 12,700 pending — means the SoftSheen-Carson litigation will test L'Oreal's litigation strategy and its balance sheet for years.

The next signal to watch is whether the Chicago federal judge pushes the parties toward a global resolution or schedules bellwether trials, the mechanism that typically sets the price of mass tort settlements.

Source: insurancejournal.com

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.

2,216 articles

Related articles

« Previous article